Trial Profile

A Two-Part, Phase 1/2a Trial to Determine the Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) Obisbemeda (Rhenium-186 NanoLiposome, 186RNL) Delivered Via Convection Enhanced Delivery (CED) in Supratentorial Recurrent, Refractory, or Progressive Pediatric Ependymoma and High-Grade Glioma (HGG)

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rhenium (186Re) obisbemeda (Primary)
Indications Brain cancer; Glioma; Meningeal carcinomatosis; Peritoneal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

26 Feb 2026 According to the Plus Therapeutics Media Release, company continue to expect first patient enrollment in our Phase 1 pediatric brain cancer trial in 2026.
21 Jul 2025 New source identified and integrated (ClinicalTrial.gov:NCT07061626)
11 Jul 2025 Status changed from planning to not yet recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com